Table 2. Analysis of drug-eluting stents (XIENCE V; TAXUS; CYPHER) compared to a bare metal stent (VISION).
| BMS (n = 56) | DES (n = 146) | p value | |
| Angiography | |||
| Baseline reference mean diameter (mm) | 2.75 ± 0.19 | 2.79 ± 0.18 | 0.118 |
| Balloon size (mm) | 3.17 ± 0.07 | 3.22 ± 0.18 | 0.732 |
| Balloon: artery ratio | 1.16 ± 0.09 | 1.15 ± 0.09 | 0.923 |
| Stent: artery ratio | 1.13 ± 0.03 | 1.12 ± 0.04 | 0.065 |
| Histology* | |||
| Endothelialization (%) | 99.11 ± 1.99 | 96.84 ± 6.60 | 0.012 |
| IEL (mm2) | 6.18 ± 0.68 | 6.97 ± 0.95 | 0.001 |
| Lumen area (mm2) | 3.86 ± 1.72 | 4.73 ± 1.58 | 0.001 |
| Neointima area (mm2) | 2.32 ± 1.26 | 1.98 ± 1.30 | 0.117 |
| Mean neointimal thickness (mm) | 0.32 ± 0.25 | 0.22 ± 0.22 | 0.011 |
| Area stenosis (%) | 39.10 ± 23.37 | 29.88 ± 19.32 | 0.009 |
| Injury score | 0.67 ± 0.44 | 0.99 ± 0.79 | 0.004 |
| Inflammation score | 0.64 ± 0.98 | 2.09 ± 1.54 | < 0.001 |
| Number of slides with the presence of para-strut granuloma formation | 3 (2%) | 50 (34%) | < 0.001 |
BMS, bare metal stent; DES, drug-eluting stent; IEL, internal elastic lamina.
* 28 days of follow-up.